Merus N.V. (MRUS)
NASDAQ: MRUS · Real-Time Price · USD
51.60
-1.09 (-2.07%)
Oct 21, 2024, 4:00 PM EDT - Market closed
Merus Revenue
Merus had revenue of $7.33M in the quarter ending June 30, 2024, a decrease of -30.01%. This brings the company's revenue in the last twelve months to $35.19M, down -14.63% year-over-year. In the year 2023, Merus had annual revenue of $43.95M with 5.68% growth.
Revenue (ttm)
$35.19M
Revenue Growth
-14.63%
P/S Ratio
84.93
Revenue / Employee
$153,681
Employees
229
Market Cap
3.52B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 43.95M | 2.36M | 5.68% |
Dec 31, 2022 | 41.59M | -7.52M | -15.32% |
Dec 31, 2021 | 49.11M | 19.16M | 64.00% |
Dec 31, 2020 | 29.94M | -1.19M | -3.82% |
Dec 31, 2019 | 31.13M | -7.25M | -18.88% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Haemonetics | 1.33B |
Prestige Consumer Healthcare | 1.11B |
HUTCHMED (China) | 610.81M |
Amicus Therapeutics | 455.66M |
Axonics | 408.81M |
ADMA Biologics | 330.24M |
Alvotech | 308.73M |
PROCEPT BioRobotics | 176.58M |
MRUS News
- 2 months ago - Merus: Great European Oncology Developer, But Properly Valued - Seeking Alpha
- 2 months ago - Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update - GlobeNewsWire
- 3 months ago - Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC - GlobeNewsWire
- 5 months ago - Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting - GlobeNewsWire
- 5 months ago - Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting - GlobeNewsWire
- 5 months ago - Merus Announces Pricing of Upsized Public Offering of Common Shares - GlobeNewsWire
- 5 months ago - Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Merus N.V. Announces Proposed Public Offering of Common Shares - GlobeNewsWire